Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients

Launched by MỸ ĐỨC HOSPITAL · Jan 25, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at two different ways to prepare the lining of the uterus for women with adenomyosis who are planning to use frozen embryos in their IVF (in vitro fertilization) treatment. The main goal is to find out if using a combination of medications (a GnRH agonist and letrozole) before the embryo transfer leads to a higher chance of having a successful pregnancy, compared to a standard treatment with just hormones. Additionally, the trial will gather information on any side effects that might come from using the combination of medications.

To take part in the trial, women must be between 18 and 42 years old, have been diagnosed with adenomyosis through an ultrasound or MRI, and have had no more than three prior IVF attempts. Participants will be randomly assigned to one of two groups: one will receive the combination treatment before their embryo transfer, and the other will get the standard hormone treatment. Throughout the process, the trial will monitor any side effects experienced by those in the combination treatment group. This study is currently recruiting participants, and it’s important to note that women with certain health conditions or previous treatments may not be eligible.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Confirm diagnosis with adenomyosis by using transvaginal ultrasonography (MUSA consensus) and/or pelvic magnetic resonance imaging.
• • Age between 18 - 42
• • Undergo less or equal to three previous IVF cycles
• • Indicate for frozen embryo transfer
• • Agree to have not more than two day-3 embryo or one blastocyst (day-5 and day-6) transferred
• • Not participating in any other study
• Exclusion Criteria:
• • Embryos from IVM cycle
• • Having uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal leiomyoma, or leiomyoma with endometrial cavity distortion)
• • Having contraindications for exogenous hormones administration: breast cancer, risks of venous thromboembolism
• • Embryos from the oocyte donation cycle.
• • Patients with a history of GnRH injection within three months, measured from the last GnRHa injection to the study screening date.